Skip to main content
Log in

The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting

Die neue ESC-Leitlinie zum akuten Koronarsyndrom und ihre Auswirkungen auf die Chest Pain Unit und zentrale Notaufnahme

  • Main topic
  • Published:
Herz Aims and scope Submit manuscript

Abstract

The new guideline on acute coronary syndrome (ACS) of the European Society of Cardiology (ESC) replaces two separate guidelines on ST-elevation myocardial infarction (STEMI) and non-ST-elevation (NSTE) ACS. This change of paradigm reflects the experts view that the ACS is a continuum, starting with unstable angina and ending in cardiogenic shock or cardiac arrest due to severe myocardial ischemia. Secondary, partly non-atherosclerotic-caused myocardial infarctions (“type 2”) are not integrated in this concept.

With respect to acute care in the setting of emergency medicine and the chest pain unit structures, the following new aspects have to be taken into account:

1. New procedural approach as “think A.C.S.” meaning “abnormal ECG,” “clinical context,” and “stable patient”

2. New recommendation regarding a holistic approach for frail patients

3. Revised recommendations regarding imaging and timing of invasive strategy in suspected NSTE-ACS

4. Revised recommendations for antiplatelet and anticoagulant therapy in STEMI

5. Revised recommendations for cardiac arrest and out-of-hospital cardiac arrest

6. Revised recommendations for in-hospital management (starting in the CPU/ED) and ACS comorbid conditions

In summary, the changes are mostly gradual and are not based on extensive new evidence, but more on focused and healthcare process-related considerations.

Zusammenfassung

Die neue Leitlinie zum akuten Koronarsyndrom (ACS) der Europäischen Gesellschaft für Kardiologie (ESC) ersetzt 2 separate Leitlinien zum ST-Hebungs-Infarkt („ST-elevation myocardial infarction“, STEMI) und zum ACS ohne ST-Hebungen („non-ST-elevation“, NSTE-ACS). Dieser Paradigmenwechsel spiegelt die Expertenperspektive wider, dass das ACS ein Kontinuum darstellt, das mit einer instabilen Angina pectoris beginnt und mit einem kardiogenen Schock oder Herzstillstand aufgrund einer schweren Myokardischämie endet. Sekundäre, teilweise nichtatherosklerotisch bedingte Myokardinfarkte („Typ 2“) sind in dieses Konzept nicht integriert. Im Hinblick auf die Akutversorgung im Rahmen der Notfallmedizin und der Chest-Pain-Unit-Strukturen (CPU) sind folgende neue Aspekte zu berücksichtigen:

1. Neuer prozessualer Ansatz als „think A.C.S.“, d. h. „abnormales EKG“, „klinischer Kontext“ und „stabiler Patient“

2. Neue Empfehlung für einen ganzheitlichen Ansatz bei gebrechlichen Patienten

3. Überarbeitete Empfehlungen zur Bildgebung und zum Zeitpunkt der invasiven Strategie bei Verdacht auf NSTE-ACS

4. Überarbeitete Empfehlungen zur Thrombozytenaggregationshemmer- und Antikoagulanzientherapie bei STEMI

5. Revidierte Empfehlungen für Herzstillstand und außerklinischen Herzstillstand

6. Überarbeitete Empfehlungen für das Management im Krankenhaus (beginnend in der Notaufnahme/CPU) und für ACS-Komorbiditäten

Zusammenfassend lässt sich sagen, dass die Änderungen größtenteils schrittweise erfolgen und nicht auf massiven neuen Erkenntnissen beruhen, sondern eher auf gezielten und prozessbezogenen Überlegungen zum Versorgungsprozess.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720–3826

    Article  CAS  PubMed  Google Scholar 

  2. Apple FS, Wu AH, Mair J et al (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51(5):810–824

    Article  CAS  PubMed  Google Scholar 

  3. Searle J, Danne O, Müller C, Mockel M (2011) Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Minerva Cardioangiol 59(3):203–223

    CAS  PubMed  Google Scholar 

  4. Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289–1367

    Article  PubMed  Google Scholar 

  5. Giannitsis E, Blankenberg S, Christenson RH et al (2021) Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clin Res Cardiol 110(9):1353–1368

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chung K, Wilkinson C, Veerasamy M, Kunadian V (2021) Frailty scores and their utility in older patients with cardiovascular disease. Interv Cardiol 16:e5

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rockwood K, Song X, MacKnight C et al (2005) A global clinical measure of fitness and frailty in elderly people. Cmaj 173(5):489–495

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ekerstad N, Pettersson S, Alexander K et al (2018) Frailty as an instrument for evaluation of elderly patients with non-ST-segment elevation myocardial infarction: a follow-up after more than 5 years. Eur J Prev Cardiol 25(17):1813–1821

    Article  PubMed  Google Scholar 

  9. Yoshioka N, Takagi K, Morita Y et al (2019) Impact of the clinical frailty scale on mid-term mortality in patients with ST-elevated myocardial infarction. Int J Cardiol Heart Vasc 22:192–198

    PubMed  PubMed Central  Google Scholar 

  10. Lee KK, Bularga A, O’Brien R et al (2021) Troponin-guided coronary computed tomographic angiography after exclusion of myocardial infarction. J Am Coll Cardiol 78(14):1407–1417

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Thygesen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40(3):237–269

    Article  PubMed  Google Scholar 

  12. Giannitsis E, Garfias-Veitl T, Slagman A et al (2022) Biomarkers-in-cardiology 8 RE-VISITED-consistent safety of early discharge with a dual marker strategy combining a normal hs-cTnT with a normal copeptin in low-to-intermediate risk patients with suspected acute coronary syndrome—a secondary analysis of the randomized biomarkers-in-cardiology 8 trial. Cells 11(2)

  13. Lindner T, Slagman A, Senkin A et al (2015) Medical history of elderly patients in the emergency setting: not an easy point-of-care diagnostic marker. Emerg Med Int 2015:490947

    Article  PubMed  PubMed Central  Google Scholar 

  14. Möckel M, Searle J, Hamm C et al (2015) Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36(6):369–376

    Article  PubMed  Google Scholar 

  15. Riedlinger D, Möckel M, Müller C et al (2018) High-sensitivity cardiac troponin T for diagnosis of NSTEMI in the elderly emergency department patient: a clinical cohort study. Biomarkers 23(6):551–557

    Article  CAS  PubMed  Google Scholar 

  16. Searle J, Slagman A, Stockburger M et al (2015) Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J Acute Cardiovasc Care 4(5):393–402

    Article  PubMed  Google Scholar 

  17. Slagman A, Searle J, Müller C, Möckel M (2015) Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction. Clin Chem 61(10):1273–1282

    Article  CAS  PubMed  Google Scholar 

  18. Vafaie M, Slagman A, Möckel M et al (2016) Prognostic value of undetectable hs Troponin T in suspected acute coronary syndrome. Am J Med 129(3):274–282.e2

    Article  CAS  PubMed  Google Scholar 

  19. Montalescot G, van ’t Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371(11):1016–1027

    Article  PubMed  Google Scholar 

  20. Möckel M (2023) Perspectives on cardiovascular biomarkers: one fits all biomarkers are out, personalization is in. Biomarkers 28(4):353

    Article  PubMed  Google Scholar 

  21. Möckel M (2020) One fits all hs troponin or more personalized dual markers strategies in the primary diagnostic assessment of patients with suspected acute coronary syndrome? Biomarkers 25(8):611–612

    Article  PubMed  Google Scholar 

  22. Möckel M (2022) Actual guidelines on non-ST-elevation acute coronary syndrome: how do they help in the emergency department? Eur J Emerg Med 29(1):2–4

    Article  PubMed  Google Scholar 

  23. Dörler J, Edlinger M, Alber HF et al (2011) Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 32(23):2954–2961

    Article  PubMed  Google Scholar 

  24. Lapostolle F, Van’t Hof AW, Hamm CW et al (2019) Morphine and ticagrelor interaction in primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: ATLANTIC-morphine. Am J Cardiovasc Drugs 19(2):173–183

    Article  CAS  PubMed  Google Scholar 

  25. Desch S, Freund A, Akin I et al (2021) Angiography after out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med 385(27):2544–2553

    Article  PubMed  Google Scholar 

  26. Desch S, Freund A, Akin I et al (2023) Coronary angiography after out-of-hospital cardiac arrest without ST-segment elevation: one-year outcomes of a randomized clinical trial. JAMA Cardiol 8(9):827–834

    Article  PubMed  Google Scholar 

  27. Lemkes JS, Janssens GN, van der Hoeven NW et al (2019) Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med 380(15):1397–1407

    Article  PubMed  Google Scholar 

  28. Lemkes JS, Janssens GN, van der Hoeven NW et al (2020) Coronary angiography after cardiac arrest without ST segment elevation: one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol 5(12):1358–1365

    Article  PubMed  Google Scholar 

  29. Hassager C, Schmidt H, Møller JE et al (2023) Duration of device-based fever prevention after cardiac arrest. N Engl J Med 388(10):888–897

    Article  PubMed  Google Scholar 

  30. Bharadwaj A, Potts J, Mohamed MO et al (2020) Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 41(23):2183–2193

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin Möckel FESC, FAHA.

Ethics declarations

Conflict of interest

M. Möckel declares speakers honoraria and consulting fees from BRAHMS GmbH, Roche Diagnostics and AstraZeneca and research support from Roche Diagnostics.

For this review article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Möckel, M. The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting. Herz (2024). https://doi.org/10.1007/s00059-024-05241-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00059-024-05241-6

Keywords

Schlüsselwörter

Navigation